E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bleeding in patients undergoing complex cardiac surgery (involving CPB) |
Sangrado en pacientes sometidos a cirugía cardíaca compleja (con CEC) |
|
E.1.1.1 | Medical condition in easily understood language |
Bleeding in patients undergoing complex cardiac surgery involving Cardiopulmonary bypass |
Sangrado en pacientes sometidos a cirugía cardiaca compleja con circulación extracorpórea |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017501 |
E.1.2 | Term | Functional disturbances following cardiac surgery |
E.1.2 | System Organ Class | 100000004863 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to evaluate the efficacy of FGTW in combination with Standard of care in reducing the need for allogeneic transfusions within the first 24 hours after randomization in complex cardiac surgery patients. |
El objetivo principal del estudio es evaluar la eficacia del FGTW en combinación con el tratamiento habitual para reducir la necesidad de transfusiones alogénicas durante las primeras 24 horas después de la aleatorización en pacientes que se han sometido a una intervención quirúrgica cardíaca compleja. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy associated with the use of FGTW versus Placebo in reducing the number and volume of RBC, FFP, and platelet concentrate transfusions in the 24 hours after randomization until hospital discharge - To evaluate the efficacy associated with the use of FGTW versus Placebo in reducing the blood drainage volume within 12 hours after randomization - To evaluate the number of patients with total avoidance of allogeneic transfusions after randomization - To evaluate the safety of FGTW - To evaluate the impact of FGTW on mortality and surgical morbidity |
Los objetivos secundarios del estudio son los siguientes: • Evaluar la eficacia del uso del FGTW en comparación con la del placebo para reducir el número y el volumen de transfusiones de eritrocitos (ERI), plasma fresco congelado (PFC) y concentrado de plaquetas durante las 24 horas siguientes a la aleatorización y hasta recibir el alta hospitalaria • Evaluar la eficacia del uso del FGTW en comparación con la del placebo para reducir el volumen de drenaje sanguíneo durante las 12 horas siguientes a la aleatorización • Evaluar el número de pacientes que han podido evitar por completo las transfusiones alogénicas después de la aleatorización • Evaluar la seguridad del FGTW • Evaluar los efectos del FGTW en la mortalidad y en la morbilidad quirúrgica |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A patient must meet all the following criteria to be eligible to participate in this study: 1. Male or female adult patients ≥18 years 2. Patients undergoing a planned complex cardiac surgery procedure involving CPB, including reoperation and/or complex surgical procedures. Complex surgical procedures are defined as any procedure other than first time isolated coronary artery bypass grafting (CABG), single valve repair/replacement and repair of atrial septal defect (ASD). This criterion represents the main eligibility criterion and so used in the definition of the full analysis set. 3. With a FIBTEM MCF ≤8 mm during the last 20 minutes of CPB. 4. Patients requiring an IMP dose ≤8 g calculated with the formula based on patient’s weight and the value of FIBTEM MCF 5. Signed and dated informed consent form (ICF) 6. Willingness to comply with all study procedures and availability for the duration of the study 7. Covered by healthcare insurance in accordance with local requirements |
Los pacientes deben cumplir todos los criterios siguientes para que se les considere aptos para participar en este estudio: 1. Pacientes adultos de ambos sexos ≥18 años 2. Pacientes que se van a someter a un procedimiento quirúrgico cardíaco complejo con CEC, incluida la repetición de operaciones o procedimientos quirúrgicos complejos. Se consideran procedimientos quirúrgicos complejos todos aquellos que no sean un primer injerto aislado de derivación en una arteria coronaria (IDAC), la reparación o sustitución de una sola válvula y la reparación de una comunicación interauricular (CIA). Este criterio es el principal a la hora de determinar la aptitud para el estudio y así se ha usado en la definición del conjunto completo de análisis 3. Con un MCF en el FIBTEM 8 mm durante los últimos 20 minutos de la CEC 4. Pacientes que necesitan una dosis 8 g de PMI calculada con la fórmula basada en el peso y el valor del MCF en el FIBTEM 5. Documento de consentimiento informado (DCI) firmado y fechado 6. Predisposición para someterse a todos los procedimientos del estudio y disponibilidad durante el transcurso del estudio 7. Cubierto por un seguro sanitario de acuerdo con los requisitos locales |
|
E.4 | Principal exclusion criteria |
A patient who meets any of the following criteria will be excluded from participation in this study: 1. Heart transplantation 2. Repair of complex congenital abnormalities 3. Any known pulmonary, hepatic, or renal disease or any other major concomitant significant medical condition that might interfere with treatment evaluation according to the Investigator’s judgment 4. Known hypersensitivity or other severe reaction to any component of the IMP 5. Patients at high risk of thrombotic events unable to stop prophylactic low-molecular-weight heparin (LMWH) 12 hours and fondaparinux 24 hours before surgery (longer interval in case of impaired renal function) 6. Patients unable to stop treatment by vitamin K antagonists 3-5 days before surgery to obtain an international normalized ratio (INR) <1.5 7. Patients unable to stop treatment by direct oral anticoagulant at least 48 hours before surgery (except aspirin) 8. Patients unable to stop treatment by P2Y12 inhibitors before surgery (discontinuation duration before surgery: ticagrelor 3 days, clopidogrel 5 days, and prasugrel 7 days) [30] 9. Severe anemia with hemoglobin (Hb) ≤10 g/dL 10. Excessive hemodilution during CPB with hematocrit (Ht) <22% in men and women 11. Congenital coagulation deficiencies (von Willebrand disease, factor V Leiden, Protein C deficiency, cryoglobulinemia, antiphospholipid syndrome…) 12. Any known thromboembolic disorder 13. Female of reproductive potential not using effective contraception (condoms; occlusive caps with spermicide; injectable, patch, or combined oral estro-progestative or progestative contraceptives; depot intramuscular medroxyprogesterone; or subcutaneous implants of progestative contraceptive implants) for at least one month prior to screening 14. Known pregnancy or positive blood pregnancy test for women of childbearing potential and/or breast-feeding women 15. Participation in another clinical study involving an investigational medicinal product within 30 days prior to screening or concomitantly with this study 16. Previous cardiac surgical procedure within three months before randomization 17. Evidence or suspicion of infection (fever >38.5°C and white blood cell count >11/mm3) 18. Active endocarditis 19. Emergency surgery, patients in cardiogenic shock, or expected mortality within 24 hours of surgery 20. Pre-existing thrombocytopenia with platelet count < 150 000/ mm3 |
Se excluirá de participar en el estudio a los pacientes que cumplan alguno de los siguientes criterios: 1. Trasplante de corazón 2. Reparación de anomalías congénitas complejas 3. Enfermedades pulmonares, hepáticas o renales conocidas, u otras afecciones médicas significativas concomitantes importantes que puedan interferir en la evaluación del tratamiento a juicio del investigador 4. Hipersensibilidad conocida u otras reacciones graves a los componentes del PMI 5. Pacientes con un riesgo elevado de sufrir acontecimientos trombóticos que no pueda interrumpir el uso profiláctico de heparina de bajo peso molecular (HBPM) 12 horas antes de la intervención quirúrgica y fondaparinux 24 horas antes de la intervención quirúrgica (intervalos mayores en caso de disfunción renal) 6. Pacientes que no puedan interrumpir un tratamiento con antagonistas de la vitamina K entre 3 y 5 días antes de la intervención quirúrgica para obtener un índice internacional normalizado (INR) <1,5 7. Pacientes que no puedan interrumpir un tratamiento con anticoagulantes orales directos 48 horas antes de la intervención quirúrgica (excepto aspirina) 8. Pacientes que no puedan interrumpir un tratamiento con inhibidores de P2Y12 antes de la intervención quirúrgica (duración de la interrupción antes de la intervención quirúrgica: ticagrelor 3 días, clopidogrel 5 días y prasugrel 7 días) 9. Anemia grave con concentraciones de hemoglobina (Hb) ≤10 g/dl 10. Hemodilución excesiva durante la CEC con hematocrito (Hto) <22 % en ambos sexos 11. Deficiencias de coagulación congénitas (enfermedad de von Willebrand, factor V Leiden, carencia de proteína C, crioglobulinemia, síndrome antifosfolipídico, etc.) 12. Trastornos tromboembólicos conocidos 13. Mujeres en edad fértil que no usen anticonceptivos eficaces (preservativos; capuchones cervicales con espermicida; anticonceptivos por vía oral, en parches o inyectables gestágenos o estrogestágenos; medroxiprogesterona intramuscular de liberación lenta; o inserción subcutánea de implantes anticonceptivos gestágenos) durante al menos un mes antes de la selección 14. Embarazo conocido o resultados positivos en la prueba del embarazo en el caso de mujeres en edad fértil o mujeres que estén dando el pecho 15. Participación en otro ensayo clínico con un medicamento en investigación en los 30 días anteriores a la selección o al mismo tiempo que este estudio 16. Procedimiento quirúrgico cardíaco anterior en los 3 meses anteriores a la aleatorización 17. Infección presunta o confirmada (>38,5 °C de fiebre y número de leucocitos >11/mm3) 18. Endocarditis activa 19. Intervención quirúrgica de urgencia en pacientes con choque cardiógeno, o mortalidad esperada durante las 24 horas siguientes a la intervención 20. Trombocitopenia preexistente con un número de plaquetas <150 000/mm3 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy endpoint The primary efficacy endpoint is the number of units of allogeneic blood products (RBC plus FFP plus platelet concentrate) given to patients between randomization and 24 hours thereafter. |
El criterio de valoración principal de la eficacia es el número de unidades de hemoderivados alogénicos (ERI, PFC y concentrado de plaquetas) administrado a los pacientes entre la aleatorización y 24 horas después. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be evaluated 24 hours after randomization. |
El criterio de valoración principal será evaluado 24 horas después de la aleatorización |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints are defined as follows: 1. Blood drainage volume within 12 hours after randomization 2. Percentage of patients with total avoidance of allogeneic transfusions within 24 hours after randomization 3. Number of transfusion units infused in the 24 hours after randomization until hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate) 4. Volume of transfusion units infused in the 24 hours after randomization until hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate) 5. Number of pre-donated autologous RBC concentrate units, RBC concentrate prepared by cell-saver, colloids, and crystalloids after randomization 6. Mortality at 24 hours, 7 days, and 30 days after randomization 7. Percentage of patients with each surgical morbidity at 24 hours, 7 days, and 30 days after randomization (see Section 9.2.8) 8. Percentage of patients with post-surgery stage 1 AKI (with increase in creatinine by >50% from baseline until EoS visit) 9. Percentage of patients with surgical re-exploration for bleeding within 24 hours after randomization 10. Percentage of patients with fibrinogen concentration below the LLN until hospital discharge 11. Percentage of patients receiving aPCCs, rFVIIa, cryoprecipitate or additional FC as rescue therapy within 24 hours after randomization |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The timepoints for the secondary end points listed under E.5.2 are as follows: 1. Within 12 hours after randomization 2. Within 24 hours after randomization 3. In the 24 hours after randomization until hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate) 4. In the 24 hours after randomization until hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate) 5. After randomization 6. At 24 hours, 7 days, and 30 days after randomization 7. At 24 hours, 7 days, and 30 days after randomization 8. From baseline until EoS visit 9. Within 24 hours after randomization 10. From the point fibrinogen concentration is below the LLN until hospital discharge 11. Within 24 hours after randomization |
Los tiempos para los criterios de valoración secundarios listados en E.5.2.son: 1. En las 12 horas posteriores a aleatorización 2. En las 24 horas posteriores a aleatorización 3. En las 24 horas posteriores a aleatorización hasta alta hospitalaria para cada clase de prod sanguíneo alogénico 4. En 24 horas posteriores a aleatorización hasta alta hospitalaria para cada clase de prod sanguíneo alogénico 5. Después de aleatorización 6. A las 24 horas, 7 días y 30 días después de aleatorización 7. A las 24 horas, 7 días y 30 días después de aleatorización 8. Desde el inicio hasta la visita de fin 9. En las 24 horas posteriores a aleatorización 10. Desde que concentración de fibrinógeno está por debajo del LLN hasta el alta hospitalaria 11. En las 24 horas posteriores a aleatorización |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Sweden |
Spain |
Germany |
Italy |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
ultima Visita del ultimo Paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 3 |